

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		ATTY DOCKET NO. <b>5045-56103USCIP</b>		APPLICATION NO. 06/860,577	
		APPLICANT <i>Eugenio Cafati, et al.</i>			
		FILING DATE 31 October 1997		GROUP <b>1615</b>	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
DOCUMENTS SUBMITTED UNDER MPEP § 724	

	<b>Expert Report of Cheryl D. Blume, Ph.D. (January 27, 2004)</b> - Subject to Protective Order
	<b>Expert Report of Dr. Sergio Fazio (February 4, 2004) [Redacted Version]</b> - Subject to Protective Order
	<b>Rebuttal Expert Report of Dr. Sergio Fazio (April 2, 2004)</b> - Subject to Protective Order
	<b>Expert Report of Dr. Sergio Fazio Regarding U.S. Patent No. 6,676,967 (August 17, 2004)</b> - Subject to Protective Order
	<b>Expert Report of Don W. Martens (February 6, 2004) [Redacted Version]</b> - Subject to Protective Order
	<b>Expert Report of Don W. Martens Regarding U.S. Patent No. 6,676,967 (August 20, 2004) [Redacted Version]</b> - Subject to Protective Order
	<b>Expert Report of Dr. Joseph R. Robinson (February 5, 2004) [Redacted Version]</b> - Subject to Protective Order
	<b>Expert Report of Dr. Joseph R. Robinson Regarding U.S. Patent No. 6,676,967 (August 18, 2004)</b> - Subject to Protective Order

EXAMINER <i>L. Channarayana</i>	DATE CONSIDERED <i>12/29/05</i>
---------------------------------	---------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO 1449 (modified)		ATTY DOCKET NO. <b>5045-56103USCIP</b>	APPLICATION NO. 03/680,677
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT <b>Eugenio Cafal, et al.</b>	
		FILING DATE <b>31 October 1997</b> <b>JAN 04 2005</b> <b>OFFICE OF PETITIONS</b>	GROUP <b>1615</b>
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
<b>DOCUMENTS SUBMITTED UNDER MPEP § 724</b>			
		<b>Rebuttal Expert Report of Thomas S. Foster, Pharm.D. (April 2, 2004)</b> - Subject to Protective Order	
		<b>Rebuttal Expert Report of Thomas S. Foster, Pharm.D.</b> <b>Regarding The '967 Patent (October 4, 2004)</b> - Subject to Protective Order	
		<b>Rebuttal Expert Report of James W. McGinity, Ph.D. (April 2, 2004)</b> - Subject to Protective Order	
		<b>Supplemental Rebuttal Expert Report of James W. McGinity, Ph.D. (August 18, 2004)</b> - Subject to Protective Order	
		<b>Rebuttal Expert Report of James W. McGinity, Ph.D.</b> <b>Regarding The '967 Patent (September 30, 2004)</b> - Subject to Protective Order	
		<b>Expert Report of Mark E. McGovern, M.D. (February 6, 2004)</b> - Subject to Protective Order	
		<b>Expert Report of Mark E. McGovern, M.D. (August 20, 2004)</b> - Subject to Protective Order	
		<b>Expert Report of Frank M. Sacks, M.D. (April 2, 2004)</b> - Subject to Protective Order	
		<b>Expert Report of Frank M. Sacks, M.D. (August 20, 2004)</b> - Subject to Protective Order	
		<b>Rebuttal Expert Report of Mary Ann Tucker, Esq. (April 2, 2004)</b> - Subject to Protective Order	
	<b>Rebuttal Expert Report of Mary Ann Tucker, Esq.</b> <b>Regarding The '967 Patent (October 1, 2004)</b> - Subject to Protective Order		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 6

*L. Channarayjale*

*12/29/05*

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)	ATTY DOCKET NO. <b>5045-56103USCIP</b>	APPLICATION NO. 02/060,577
	APPLICANT <i>Eugenio Cefali, et al.</i>	
	FILING DATE 31 October 1997	GROUP <b>1815</b>
OTHER DOCUMENT(S) (including Author, Title, Date, Pertinent Pages, Etc.)		
<b>DOCUMENTS SUBMITTED UNDER MPEP § 724</b>		
		<del>Sample Kos Clinical Trial Medical Consent Form</del> <del>- Subject to Protective Order</del>
		<del>Sample Kos Clinical Trial Investigator's Statement</del> <del>- Subject to Protective Order</del>
EXAMINER	<i>R. Channarayana</i>	DATE CONSIDERED <i>12/29/05</i>





\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)		ATTY DOCKET NO. <b>5045-56103USCIP</b>	APPLICATION NO. 08/680,577
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT <b>Eugenio Cefali, et al.</b>	
		<div style="text-align: center;"><b>RECEIVED</b></div> <div style="display: flex; justify-content: space-between;"> <span>JAN 04 2005</span> <span>GROUP 1615</span> </div>	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		FILING DATE 31 October 1997	
<b>OFFICE OF PETITIONS</b>			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	<b>Carl J. Lavie, et al., <i>Marked Benefit with Sustained-Release Niacin Therapy in Patients with "Isolated" Very Low Levels of High-Density Lipoprotein Cholesterol and Coronary Artery Disease</i>, Am. J. Cardiol. 1992:69:1083-1085</b>		
	<b>Excerpts from the 1993, 2000 and 2002 editions of the Physician's Desk Reference</b> 1993 edition (pp. 434, 611, 856, 1189, 1919, 1920, 2491 and 2492) 2000 edition (pp. 1519-1523) 2002 edition (pp. 1846-1850)		
	<b><i>Niacin: Double-edged Sword for Lowering Cholesterol</i>, Tufts University Diet &amp; Nutritional Letter (Tufts Univ., Boston, MA), August 1994, Vol. 12, issue 6</b>		
	<b>Larsen, ML and Illingworth, DR, <i>Drug Treatment of Dyslipoproteinemia</i>, Med Clin N Am., 78:225-245 (1994)</b>		
	<b>Lavie, Letter to Editor, JAMA 1994; 272:513-515</b>		
	<b>Keenan, Letter to Editor, JAMA 1994; 272:513-515</b>		
	<b>Shields &amp; Beckmann, Letter to Editor, JAMA 1994; 272:513-515</b>		
	<b>Thomas N. Tozer, <i>Clinical Pharmacokinetics Concepts and Applications</i> (3d ed. 1995) at Chapter 9, p. 120</b>		
	<b>Excerpts from the 1995 United States Pharmacopela (pp. iii-vi, 1080-1082, 1793-1799, 1940-1944)</b>		
	<b>Morgan &amp; Capuzzi Abstract, <i>Safe and Effective Treatment of Dyslipidemia by Niaspan, a New Sustained-Release Niacin</i>, Clinical Pharmacology &amp; Therapeutics (February 1996)</b>		
	<b>Morgan &amp; Capuzzi Article, <i>Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial</i>, J. Cardiovasc. Pharmacol. Therapeut. 1(3):195-202 (July 1996)</b>		
EXAMINER	<b>L. Channarayana</b>		DATE CONSIDERED <b>12/29/05</b>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1448 (modified)		ATTY DOCKET NO. <b>5045-56103USCIP</b>	APPLICATION NO. 08/980,577
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT <b>Eugenio Cofa, et al.</b>	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		<div style="text-align: center;"> <b>RECEIVED</b>  <b>JAN 04 2005</b> </div>	
		FILED DATE 31 October 1997	GROUP <b>1615</b>
OTHER DOCUMENT(S) (Including Author, Title, Date, Periodical, etc.)			
B		<b>Capuzzi DM, et al., Efficacy and Safety of An Extended-Release Niacin (Niaspan): A Long-Term Study, Am J Cardiol. 1998;82:74U-81U</b>	
		<b>Guyton JR, Advances in Dyslipidemia: Discussion Session II, Am J Cardiol, 1998: 82(12A): 85U-86U</b>	
		<b>Knopp RH, et al., Equivalent Efficacy of a Time-Release Form of Niacin (Niaspan) Given Once-a-Night Versus Plain Niacin in the Management of Hyperlipidemia, Metabolism 47:1097-1104 (1998)</b>	
		<b>American Diabetes Association: Management of Dyslipidemia in Adults with Diabetes, Diabetes Care 21:179-182, 1998</b>	
		<b>Elam MB, et al., Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease, JAMA: 2000; 284:1263-1270</b>	
		<b>Kesala R, et al., Niacin (N) vs. Niaspan (NS) Treatment of the Atherogenic Lipid Profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in Diabetic Patients (DP), Diabetes 49 (suppl. 1): A268 at 1114-P (June 2000)</b>	
		<b>2001 NCEP Report at VI-11, Table VI.2-3</b>	
		<b>Wang, W. et al., Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production, Am J Physiol Endocrinol Metab., 280:E540-E547 (2001)</b>	
		<b>Smith SC, et al., AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update. AHA/ACC Scientific Statement, 1577-79</b>	
V		<b>Tavintharan S and Kashyap M, The Benefits of Niacin in Atherosclerosis, Curr Athero. Reports 2001; 3:74-82</b>	
EXAMINER		DATE CONSIDERED	
L. Channarayana		12/29/02	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)		ATTY DOCKET NO. <b>5045-56103USCIP</b>	APPLICATION NO. 08/860,577
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT <b>Eugenio Cefali, et al.</b>	
		<div style="text-align: center; font-size: 1.5em; font-weight: bold;">RECEIVED</div> <div style="display: flex; justify-content: space-between;"> <span>FILING DATE 31 October 1997</span> <span>JAN 04 2005</span> <span>GROUP 1615</span> </div>	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			
OTHER DOCUMENT(S) (Including Author, Title, Date, Portion Pages, Etc.)			
	<b>Meadows M., Serious Liver Injury: Leading Reason for Drug Removals, Restrictions, FDA Consumer Magazine, May-June 2001;</b> <a href="http://www.fda.gov/fdac/features/2001/301_liver.html">http://www.fda.gov/fdac/features/2001/301_liver.html</a>		
	<b>Grundy SM, et al., Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 Diabetes. Arch Intern Med. 2002; 162: 1568-1576</b>		
	<b>American Diabetes Association: Management of Dyslipidemia in Adults with Diabetes, Diabetes Care 25:S74-S77, 2002</b>		
	<b>Pan J, et al., Niacin Treatment of the Atherogenic Lipid Profile and Lp(a) in Diabetes, Diabetes, Obesity and Metabolism 4:255-261 (2002)</b>		
	<b>Pan J, et al., Extended-Release Niacin Treatment of the Atherogenic Lipid Profile and Lipoprotein(a) in Diabetes, Metabolism 51:1120-1127 (2002)</b>		
	<b>Meyers CD, et al., Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia, Ann Intern Med. 2003; 139:996-1002</b>		
	<b>CDER Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations (March 2003)</b>		
	<b>American Diabetes Association: Dyslipidemia Management in Adults with Diabetes, Diabetes Care 27:S68-S71, 2004</b>		
EXAMINER			DATE CONSIDERED
			

Form 862

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 8 of 8